A Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, International, Multicentre Phase III Trial of PI-88 in the Adjuvant Treatment of Post-resection Hepatocellular Carcinoma.
Phase of Trial: Phase III
Latest Information Update: 23 Apr 2013
At a glance
- Drugs Muparfostat (Primary)
- Indications Liver cancer
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms PATHWAY
- Sponsors Progen Pharmaceuticals Limited
- 22 Jul 2008 Status changed from recruiting to discontinued as reported by Progen Pharmaceuticals.
- 11 Mar 2008 The first patient has been randomised.
- 21 Dec 2007 Status changed from initiated to recruiting.